Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Holobiome is a clinical-stage biotechnology company at the forefront of microbiome research, specifically focusing on the gut-brain-axis. The company aims to discover and develop groundbreaking microbial-based therapeutics (psychobiotics) to address a range of mental health conditions, including depression and anxiety, as well as other neurological disorders. By identifying specific gut bacteria that influence brain chemistry and function, Holobiome is pioneering a new class of treatments with the potential to revolutionize how these conditions are managed. Their approach involves isolating and characterizing human-derived bacteria with a demonstrated ability to produce key neurotransmitters or modulate immune pathways relevant to mental health.
Serves as the primary center for research and development, strategic planning, and corporate operations. It leverages the rich biotech ecosystem of Kendall Square, facilitating collaborations and access to top talent.
Likely housed within the Cambridge Innovation Center (CIC) or a similar multi-tenant life science facility, providing access to state-of-the-art, shared, and private laboratory facilities, modern office spaces, and collaborative environments designed to foster innovation.
Characterized by a scientifically-driven, innovative, and collaborative environment. The team is dedicated to rigorous research and translational science, aiming to make a significant impact on mental healthcare. The culture encourages intellectual curiosity and a fast-paced, mission-oriented approach.
The Cambridge location provides Holobiome with unparalleled access to world-class academic institutions (like MIT and Harvard), a dense concentration of biotech companies, leading research hospitals, a highly skilled talent pool, and venture capital, all crucial for its growth and scientific advancement.
While Holobiome's primary operations and headquarters are based in Cambridge, MA, USA, its research, intellectual property, and the potential applications of its therapeutics have global relevance. The company may engage in international collaborations for research, clinical trials, and eventually, strategic partnerships for market access to address mental health challenges on a worldwide scale. Their scientific contributions and publications reach a global audience within the research community.
245 First Street, Suite 1800
Cambridge
MA
USA
No additional office locations available.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Holobiome' leadership includes:
Holobiome has been backed by several prominent investors over the years, including:
No major public announcements regarding executive hires or exits at Holobiome have been identified in the last 12 months. The company appears to maintain a stable leadership team focused on advancing its therapeutic pipeline.
Discover the tools Holobiome uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Holobiome likely utilizes standard professional email formats. Based on common practices for companies of its size and industry, a frequently used format is the first initial followed by the last name.
[first_initial][last]@holobiome.com
Format
jdoe@holobiome.com
Example
85%
Success rate
Nature Mental Health • May 18, 2023
Philip Strandwitz, CEO of Holobiome, co-authored a perspective article titled 'Developing next-generation psychobiotics for mental health' in Nature Mental Health. The piece discusses the challenges, opportunities, and rigorous scientific approaches needed for developing effective microbial-based therapies for mental health conditions....more
Endpoints News • October 27, 2022
Holobiome secured $9.6 million in a Seed A financing round. The funding is aimed at advancing its pipeline of live biotherapeutics designed to target depression and other mental health disorders by modulating the gut-brain axis....more
TechCrunch • October 26, 2022
Holobiome announced it has raised $9.6 million in Seed A funding. The investment, co-led by General Catalyst and Seed Health, with participation from other investors, will support the development of its platform and pipeline of microbial therapeutics for mental health....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Holobiome, are just a search away.